MCID: ASP001
MIFTS: 44

Asperger Syndrome malady

Categories: Genetic diseases, Rare diseases, Mental diseases, Fetal diseases

Aliases & Classifications for Asperger Syndrome

About this section

Aliases & Descriptions for Asperger Syndrome:

Name: Asperger Syndrome 10 45 22 23 46 47 12 36 65
Asperger Disorder 45 22 23
Asperger's Syndrome 23 24
 
Asperger's Disorder 23
Asperger's Disease 23
Asperger Disease 23

Classifications:



External Ids:

Disease Ontology10 DOID:0050432
ICD1027 F84.5
MeSH36 D020817
NCIt42 C97159
UMLS65 C0236792

Summaries for Asperger Syndrome

About this section
NIH Rare Diseases:45 Asperger syndrome (as) is an autism spectrum disorder, a type of neurological condition characterized by impaired language and communication skills, and repetitive or restrictive thought and behavior patterns. unlike many people with autism, those with as retain their early language skills. features of as include an obsessive interest in a particular object or topic; high vocabulary; formal speech patterns; repetitive routines or habits; inappropriate social and emotional behavior; impaired non-verbal communication; and uncoordinated motor skills. as is likely caused by a combination of genetic and environmental influences. while autism spectrum disorders including as sometimes run in families, no specific inheritance pattern has been recognized. last updated: 6/8/2015

MalaCards based summary: Asperger Syndrome, also known as asperger disorder, is related to autism spectrum disorder and usher syndrome. An important gene associated with Asperger Syndrome is NLGN4X (Neuroligin 4, X-Linked). Affiliated tissues include brain, breast and bone, and related mouse phenotypes are endocrine/exocrine gland and growth/size/body region.

Disease Ontology:10 An autism spectrum disorder that is characterized by significant difficulties in social interaction, along with restricted and repetitive patterns of behavior and interests. It differs from other autism spectrum disorders by its relative preservation of linguistic and cognitive development.

NINDS:46 Asperger syndrome (AS) is a developmental disorder.

Genetics Home Reference:23 Asperger syndrome is a disorder on the autism spectrum, which is a group of conditions characterized by impaired communication and social interaction. Asperger syndrome is on the mild, or "high-functioning," end of the autism spectrum. Many affected individuals learn to compensate for their differences and live independent and successful lives. However, the behavioral challenges associated with this condition often lead to social isolation and difficulties at school, at work, and in personal relationships.

Wikipedia:68 Asperger syndrome (AS), also known as Aspergers, is a developmental disorder characterized by... more...

Related Diseases for Asperger Syndrome

About this section

Graphical network of the top 20 diseases related to Asperger Syndrome:



Diseases related to asperger syndrome

Symptoms for Asperger Syndrome

About this section

Drugs & Therapeutics for Asperger Syndrome

About this section

Drugs for Asperger Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 98)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 3, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Methylphenidateapproved, investigationalPhase 4364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
3
Guanfacineapproved, investigationalPhase 45329110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine
Guanfacine (INN)
Guanfacine Hydrochloride
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tenex
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
4
MilnacipranapprovedPhase 45892623-85-365833
Synonyms:
( -)-Milnacipran
(+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
(-)-milnacipran
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
105310-09-6
92623-85-3
AC1L2425
CHEMBL252923
CID65833
D08222
DB04896
F 2207
F-2207
 
F2207
Ixel
LS-178180
Midalcipran
Milnacipran
Milnacipran (INN)
Milnacipran Hydrochloride
Milnacipran [INN]
Milnacipranum
Milnacipranum [Latin]
Milnacipranum [latin]
NCGC00165825-01
Savella
Toledomin
UNII-G56VK1HF36
milnacipran
5
Risperidoneapproved, investigationalPhase 4, Phase 3477106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
 
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperdal M-tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone M-tab
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
6
Cholineapproved, nutraceuticalPhase 413062-49-7305
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(beta-hydroxyethyl)trimethylammonium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
2-Hydroxy-N,N,N-trimethylethanaminium
Bilineurine
Biocolina
Biocoline
Choline
Choline cation
 
Choline ion
Cholinum
Hepacholine
Hormocline
Lipotril
N,N,N-Trimethylethanol-ammonium
N,N,N-Trimethylethanolammonium
N,N,N-trimethylethanol-ammonium
N-trimethylethanolamine
Neocolina
Paresan
trimethylethanolamine
7
Creatineapproved, nutraceuticalPhase 411057-00-1586
Synonyms:
((amino(Imino)methyl)(methyl)amino)acetic acid
((amino(imino)methyl)(methyl)amino)acetate
((amino(imino)methyl)(methyl)amino)acetic acid
(N-methylcarbamimidamido)acetic acid
(alpha-Methylguanido)acetate
(alpha-Methylguanido)acetic acid
(α-methylguanido)acetic acid
Cosmocair C 100
Creatin
Creatine
Creatine hydrate
Kreatin
 
Krebiozon
Methylglycocyamine
Methylguanidoacetate
Methylguanidoacetic acid
N-(Aminoiminomethyl)-N-Methyl-Glycine
N-(aminoiminomethyl)-N-methylglycine
N-Amidinosarcosine
N-Carbamimidoyl-N-methylglycine
N-Methyl-N-guanylglycine
N-[(e)-AMINO(imino)methyl]-N-methylglycine
Phosphagen
[[Amino(imino)methyl](methyl)amino]acetate
[[Amino(imino)methyl](methyl)amino]acetic acid
alpha-Methylguanidino acetic acid
8Tranquilizing AgentsPhase 4, Phase 3, Phase 23597
9Atomoxetine HydrochloridePhase 4, Phase 3160
10Adrenergic alpha-2 Receptor AgonistsPhase 4790
11Adrenergic AgentsPhase 4, Phase 3, Phase 24204
12Antihypertensive AgentsPhase 43618
13Adrenergic alpha-AgonistsPhase 41300
14
PhosphocreatinePhase 4667-07-2587
Synonyms:
Creatine phosphate
Creatine-P
Creatine-phosphate
Creatinephosphoric acid
N-(Phosphonoamidino)-Sarcosine
N-(Phosphonoamidino)sarcosine
 
N-Phosphocreatine
N-Phosphorocreatine
N-Phosphorylcreatine
N-[Imino(phosphonoamino)methyl]-N-methyl-Glycine
Neo-ton
P-Creatine
Phosphocreatine
Phosphorylcreatine
15Adrenergic AgonistsPhase 42331
16Serotonin AntagonistsPhase 4, Phase 3, Phase 21175
17Psychotropic DrugsPhase 4, Phase 3, Phase 25501
18
SerotoninPhase 4, Phase 3, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
19Neurotransmitter Uptake InhibitorsPhase 4, Phase 3, Phase 22857
20Dopamine AntagonistsPhase 4, Phase 3, Phase 2927
21Antidepressive AgentsPhase 4, Phase 3, Phase 22367
22Serotonin AgentsPhase 4, Phase 3, Phase 22668
23Neurotransmitter AgentsPhase 4, Phase 3, Phase 214795
24Serotonin Uptake InhibitorsPhase 4, Phase 21369
25Central Nervous System DepressantsPhase 4, Phase 3, Phase 210016
26Dopamine AgentsPhase 4, Phase 3, Phase 23084
27Antipsychotic AgentsPhase 4, Phase 3, Phase 22130
28Dopamine Uptake InhibitorsPhase 4925
29Central Nervous System StimulantsPhase 41721
30Rho(D) Immune GlobulinPhase 4206
31Immunologic FactorsPhase 418483
32ImmunoglobulinsPhase 44477
33Immunoglobulins, IntravenousPhase 4211
34AntibodiesPhase 44477
35
CycloserineapprovedPhase 310368-41-7401, 6234
Synonyms:
(+)-4-Amino-3-isoxazolidinone
(+)-Cycloserine
(4R)-4-Amino-3-isoxazolidinone
(4R)-4-amino-1,2-oxazolidin-3-one
(4R)-4-aminoisoxazolidin-3-one
(R)-(+)-4-Amino-3-isoxazolidinone
(R)-(+)-Cycloserine
(R)-4-AMINO-ISOXAZOLIDIN-3-ONE
(R)-4-AMINO-isoxazolidin-3-one
(R)-4-Amino-3-isoxazolidinone
(R)-4-Amino-3-isoxazolidone
(R)-Cycloserine
1pb9
3-Isoxazolidinone, 4-amino-, (+)- (8CI)
3-Isoxazolidinone, 4-amino-, (4R)- (9CI)
3-Isoxazolidinone, 4-amino-, (R)
3-Isoxazolidinone, 4-amino-, D
30020_FLUKA
30020_SIGMA
4-27-00-05549 (Beilstein Handbook Reference)
4AX
68-41-7
AB00443920
AC-4721
AC1L1M33
AC1Q4UA7
AI3-50153
BB_NC-1631
BIDD:GT0707
BPBio1_001252
BRN 0080798
BSPBio_001138
BSPBio_002121
C 3909
C-9390
C-9400
C08057
C3909_SIGMA
C3H6N2O2
C6880_SIGMA
C7670_SIGMA
CAS-339-72-0
CAS-68-41-7
CHEBI:40009
CHEMBL771
CID6234
CPD-2482
CPD000058313
Cicloserina
Cicloserina [INN-Spanish]
Cicloserina [Italian]
Closerin
Closina
Cyclo-D-serine
Cyclorin
Cycloserine
Cycloserine (JP15/USP/INN)
Cycloserine [INN:BAN:JAN]
Cycloserinum
Cycloserinum [INN-Latin]
D-(+)-Cycloserine
D-4-Amino-3-isossazolidone
D-4-Amino-3-isossazolidone [Italian]
D-4-amino-3-Isoxazolidinone
D-4-amino-3-Isoxazolidone
D-4-amino-3-isoxazolidinone
D-4-amino-3-isoxazolidone
D-CS
D-Cycloserine
D-Cycloserine synth. BP 88
D-Cycloserine, synthetic
D-Oxamicina
D-Oxamycin
D-amino-3-isoxazolidinone
D-cycloserine
D00877
DB03123
DCS
DL-Cycloserine
DRG-0195
DivK1c_000098
E-733-A
EINECS 200-688-4
 
EU-0100252
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09
Farmiserina
HMS1571I20
HMS1920C06
HMS2051C15
HMS2091I14
HMS500E20
HSDB 3218
I-1431
IDI1_000098
K-300
KBio1_000098
KBio2_001340
KBio2_003908
KBio2_006476
KBio3_001341
KBioGR_000890
KBioSS_001340
L-Cycloserine
LMPK14000007
LS-86757
Lopac-C-1159
Lopac-C-3909
Lopac-C-7005
Lopac0_000252
MLS000758215
MLS001423962
Micoserina
Miroserina
Miroseryn
MolPort-000-858-643
NCGC00015213-01
NCGC00015213-02
NCGC00015213-03
NCGC00016306-01
NCGC00016306-02
NCGC00016306-03
NCGC00016306-05
NCGC00093713-01
NCGC00093713-02
NINDS_000098
NSC 154851
Novoserin
Orientomycin
Oxamicina
Oxamicina [Italian]
Oxamycin
PA 94
PA-94
Prestwick0_001089
Prestwick1_001089
Prestwick2_001089
Prestwick3_001089
R(+)-4-Amino-3-isoxazolidinone
R-(+)-Cycloserine
R-4-Amino-3-isoxazolidinone
RO-1-9213
Ro-1-9213
S1998_Selleck
SAM001247014
SAM002264599
SC-49088
SMP1_000167
SMR000058313
SPBio_000008
SPBio_003029
SPECTRUM1500215
Seromycin
Seromycin (TN)
Spectrum2_000084
Spectrum3_000371
Spectrum4_000305
Spectrum5_000797
Spectrum_000860
Tebemicina
Tisomycin
UNII-95IK5KI84Z
Wasserina
alpha-Cycloserine
cyclo-D-Serine
cycloserine
orientomycin
α-Cycloserine
36
MianserinapprovedPhase 33324219-97-44184
Synonyms:
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,F)pyrazino(1,2-a)azepine
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine
2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
21535-47-7 (mono-hydrochloride)
24219-97-4
AC-631
AC1L1HLP
BPBio1_000064
BPBio1_000331
BRD-A19661776-001-01-5
BRD-A19661776-003-05-2
BRN 0755346
BSPBio_000058
BSPBio_003511
Biomol-NT_000135
Bolvidon
C18H20N2
CHEBI:51137
CHEMBL6437
CID4184
D08216
DB06148
DivK1c_000844
EINECS 246-088-6
HMS2089A04
HSDB 7182
IDI1_000844
KBio1_000844
KBio2_002301
KBio2_004869
KBio2_007437
KBio3_003016
KBioGR_001820
KBioSS_002303
L000736
LS-61197
Lopac0_000744
Mianserin (INN)
 
Mianserin Monohydrochloride
Mianserin [INN:BAN]
Mianserin hydrochloride
Mianserina
Mianserina [INN-Spanish]
Mianserina [inn-spanish]
Mianserine
Mianserine [INN-French]
Mianserine [inn-french]
Mianserinum
Mianserinum [INN-Latin]
Mianserinum [inn-latin]
Mianseryna
Mianseryna [Polish]
Mianseryna [polish]
MolPort-003-849-215
NCGC00015656-09
NCGC00024926-03
NCGC00024926-04
NINDS_000844
Norval
Oprea1_703627
PDSP1_001532
PDSP2_001516
Prestwick0_000099
Prestwick1_000099
Prestwick2_000099
Prestwick3_000099
SPBio_000986
SPBio_001997
Spectrum2_001203
Spectrum3_001836
Spectrum4_001260
Spectrum5_001772
Spectrum_001810
Tolvan
Tolvon
Tolvon (TN)
mianserin
37
ZiprasidoneapprovedPhase 3140146939-27-760854
Synonyms:
138982-67-9 (hydrochloride monohydrate)
146939-27-7
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
6-chloro-5-[2-[4-(7-thia-8-azabicyclo[4.3.0]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one
AC1L1U27
Ambap122883-93-6
BIDD:GT0042
C07568
C21H21ClN4OS
CHEBI:10119
CHEMBL708
CID60854
CP 88059
CP 88059-01
CP-88,059
CP-88,059-01
CP-88,059-1
CP-88059-1
CPD000466328
D08687
DB00246
 
Geodon
Geodon Oral
I14-0766
L000659
LS-83744
MLS000759435
MolPort-003-850-885
SAM001246607
SMR000466328
TL8000889
UNII-6UKA5VEJ6X
Zeldox
Zipradon
Zipradon (TN)
Ziprasidona
Ziprasidone
Ziprasidone (INN)
Ziprasidone Hydrochloride
Ziprasidone [INN:BAN]
Ziprasidone hydrochloride
Ziprasidone mesylate trihydrate
Ziprasidonum
ziprasidona
ziprasidonum
ziprazidone
38
MirtazapineapprovedPhase 37885650-52-8, 61337-67-54205
Synonyms:
(1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
(N-methyl-11C)mirtazapine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
6-Azamianserin
61337-67-5
82601-27-2
85650-52-8
AC-15480
AC1L1HND
AC1Q3ZYM
Avanza
Axit
Azamianserin
BRD-A64977602-001-01-9
C035133
C07570
CHEBI:6950
CHEMBL654
CID4205
CPD000466347
Celltech brand of mirtazapine
D00563
DB00370
EINECS 288-060-6
HMS2052H03
I01-1882
I06-0606
L001294
LS-127703
LS-185067
M0443_SIGMA
ME-2040
MLS000759460
MLS001076676
Mepirzapin
Mepirzapine
 
Mepirzepine
Mirtabene
Mirtaz
Mirtazapin
Mirtazapina
Mirtazapina [INN-Spanish]
Mirtazapine
Mirtazapine (JAN/USAN/INN)
Mirtazapine [USAN:BAN:INN]
Mirtazapine [USAN:INN:BAN]
Mirtazapine [Usan:Ban:Inn]
Mirtazapinum
Mirtazapinum [INN-Latin]
Mirtazepine
Mirtazipine
Mirtazon
MolPort-003-849-233
Mundogen brand of mirtazapine
NCGC00025346-02
Norset
ORG 3770
Org-3770
Organon brand of mirtazapine
PDSP1_001529
PDSP2_001513
Promyrtil
Remergil
Remergon
Remeron
Remeron (TN)
Remeron SolTab
Remeron Soltab
Remeronsoltab
Rexer
SAM001246659
SMR000466347
STK711107
UNII-A051Q2099Q
Zispin
mirtazapine
39
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
40Anti-Bacterial AgentsPhase 39140
41Antibiotics, AntitubercularPhase 35971
42Anti-Infective AgentsPhase 3, Phase 217220
43Contraceptives, OralPhase 3, Phase 23734
44Antidepressive Agents, Second-GenerationPhase 3, Phase 21087
45Antitubercular AgentsPhase 31061
46Adrenergic alpha-AntagonistsPhase 3, Phase 2586
47Adrenergic AntagonistsPhase 3, Phase 21253
48AntimetabolitesPhase 39454
49Histamine H1 AntagonistsPhase 3688
50Antidepressive Agents, TricyclicPhase 3250

Interventional clinical trials:

(show top 50)    (show all 75)
idNameStatusNCT IDPhase
1Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of AutismCompletedNCT01337700Phase 4
2Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone StudyCompletedNCT00352196Phase 4
3Atomoxetine, Placebo and Parent Management Training in AutismCompletedNCT00844753Phase 4
4Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental DisorderCompletedNCT01238575Phase 4
5Understanding the Effects of Intervention on the Brain in AutismRecruitingNCT02680015Phase 4
6Methylphenidate ER Liquid Formulation in Adults With ASD and ADHDRecruitingNCT02096952Phase 4
7An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism SpectrumActive, not recruitingNCT02199925Phase 4
8Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum DisordersCompletedNCT01178385Phase 2, Phase 3
9A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)CompletedNCT00261508Phase 3
10D-Cycloserine and Social Skills Training in Autism Spectrum DisordersCompletedNCT01086475Phase 3
11Psychotherapy for Anxiety in Children With Autism Spectrum DisorderRecruitingNCT02028247Phase 3
12Psychotherapy for Anxiety in Children With Autism Spectrum DisorderRecruitingNCT02111395Phase 3
13Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental DisordersRecruitingNCT01302964Phase 3
14Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With AutismRecruitingNCT00498173Phase 3
15An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)CompletedNCT01592786Phase 2
16Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With MemantineCompletedNCT01592747Phase 2
17CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOSCompletedNCT00280670Phase 2
18The Development of Autistic Children Based on Mothers´Response in Autism Behavior ChecklistCompletedNCT00725556Phase 1, Phase 2
19Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for AdolescentsCompletedNCT01177969Phase 1, Phase 2
20A Study of Oral N-Acetylcysteine in Children With Autism Spectrum DisordersCompletedNCT00453180Phase 2
21A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.CompletedNCT00198055Phase 2
22Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and AdolescentsCompletedNCT01731119Phase 2
23Study of Aripiprazole to Treat Children and Adolescents With AutismCompletedNCT00619190Phase 2
24My Scrivener® - Measuring Effectiveness and Dose Response in ChildrenCompletedNCT00919906Phase 1, Phase 2
25Cholesterol in ASD: Characterization and TreatmentCompletedNCT00965068Phase 1, Phase 2
26Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum DisordersCompletedNCT00251303Phase 2
27An Open-Label Trial of Aripiprazole in Autism Spectrum DisordersCompletedNCT00308074Phase 2
28Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum DisordersCompletedNCT01288716Phase 2
29Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)CompletedNCT00086645Phase 2
30Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)CompletedNCT01248728Phase 2
31Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children.RecruitingNCT01388179Phase 2
32Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)TerminatedNCT01592773Phase 2
33A Folinic Acid Intervention for Autism Spectrum DisordersTerminatedNCT01602016Phase 2
34Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in AutismTerminatedNCT01983189Phase 2
35Mercury Chelation to Treat AutismWithdrawnNCT00376194Phase 2
36Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and AnxietyCompletedNCT01187784Phase 1
37A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's SyndromeCompletedNCT01669889
38The Use of rTMS to Improve Theory of Mind Among Adults With Autism and Asperger's DisorderCompletedNCT00808782
39Advanced Grandparental Age as a Risk Factor for AutismCompletedNCT00464477
40Psychometric Studies of the Chinese Versions of the SRS, CAST, and AQCompletedNCT01247662
41Cognitive Behavioural Therapy (CBT) and Recreational Activity for Autism Spectrum Disorders (ASD)CompletedNCT01655173
42Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With AutismCompletedNCT01563003
43Predictors of Caregiver Adaptation to Pervasive Developmental DisordersCompletedNCT00496210
44Shared Decision Making to Improve Care and Outcomes for Children With AutismCompletedNCT01921244
45Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in AutismCompletedNCT00211783
46GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education ProgramsCompletedNCT01808066
47Intranasal Oxytocin for the Treatment of Autism Spectrum DisordersCompletedNCT01337687
48Neural and Behavioral Outcomes of Social Skills Groups in Children With Autism Spectrum Disorder (ASD)CompletedNCT01190917
49RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental DisordersCompletedNCT00080145
50Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum DisordersCompletedNCT01361503

Search NIH Clinical Center for Asperger Syndrome


Cochrane evidence based reviews: asperger syndrome

Genetic Tests for Asperger Syndrome

About this section

Genetic tests related to Asperger Syndrome:

id Genetic test Affiliating Genes
1 Asperger Disorder22

Anatomical Context for Asperger Syndrome

About this section

MalaCards organs/tissues related to Asperger Syndrome:

33
Brain, Breast, Bone, Kidney, Lung, T cells, Endothelial

Animal Models for Asperger Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Asperger Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053797.7ARNT2, AVPR1B, CYP11B1, OXTR, SLC6A4, WFS1
2MP:00053786.8CYP11B1, DISC1, GABRB3, NLGN3, OXTR, SHANK3
3MP:00036316.5ARNT2, AVPR1B, DISC1, GABRB3, NLGN3, OXTR
4MP:00053865.8AVPR1B, CYP11B1, DISC1, GABRB3, NLGN3, OXTR

Publications for Asperger Syndrome

About this section

Articles related to Asperger Syndrome:

(show top 50)    (show all 453)
idTitleAuthorsYear
1
Haploidentical hematopoietic stem cell transplant in paroxysmal nocturnal hemoglobinuria. (26911378)
2016
2
Effects of ER stress on unfolded protein responses, cell survival, and viral replication in primary effusion lymphoma. (26692493)
2016
3
Pancreatic stone protein/regenerating protein (PSP/reg): a novel secreted protein up-regulated in type 2 diabetes mellitus. (25234740)
2015
4
Diminished testing benefits in young adults with attention-deficit hyperactivity disorder. (25385006)
2014
5
Genetic variation rs10484761 on 6p21.1 derived from a genome-wide association study is associated with gastric cancer survival in a Chinese population. (24325909)
2014
6
Endophilin-1 regulates blood-brain barrier permeability by controlling ZO-1 and occludin expression via the EGFR-ERK1/2 pathway. (24854121)
2014
7
Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. (23582991)
2013
8
Renal sympathetic denervation as an adjunct to catheter ablation for the treatment of ventricular electrical storm in the setting of acute myocardial infarction. (24118342)
2013
9
Management strategies in the treatment of neonatal and pediatric gastroenteritis. (24194646)
2013
10
Novel CTSK mutation resulting in an entire exon 2 skipping in a Thai girl with pycnodysostosis. (24134756)
2013
11
The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. (23929529)
2013
12
MicroRNA 17-92 expressed by a transposone-based vector changes expression level of cell-cycle-related genes. (22731656)
2012
13
Molecular phylogenetics of Fonsecaea strains isolated from chromoblastomycosis patients in South Korea. (21910758)
2011
14
The neuropathology of fatal cerebral malaria in malawian children. (21514429)
2011
15
Novel genetic aspects of Klinefelter's syndrome. (20228051)
2010
16
Fine-needle aspiration in myxofibrosarcoma: experience of Institut Curie. (19899126)
2010
17
The psychosocial effects of strabismus: effect of patient demographics on the AS-20 score. (21168068)
2010
18
Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. (19499965)
2009
19
Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome. (19672700)
2009
20
Brain-derived neurotrophic factor induces sustained elevation of intracellular Ca2+ in rodent microglia. (19923466)
2009
21
Salt-inducible kinase regulates hepatic lipogenesis by controlling SREBP-1c phosphorylation. (19244231)
2009
22
Recruitment of Sprouty1 to immune synapse regulates T cell receptor signaling. (19915061)
2009
23
Leukocyte adhesion deficiency type 1: an important consideration in the clinical differential diagnosis of prepubertal periodontitis. A case report and review of the literature. (17618138)
2008
24
Sialolithiasis of the submandibular salivary gland treated with the 810- to 830-nm diode laser. (19099383)
2008
25
Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment. (19134026)
2008
26
MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. (17549610)
2007
27
A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells. (17393435)
2007
28
Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. (18022071)
2007
29
Argatroban therapy in women with heparin-induced thrombocytopenia. (17678460)
2007
30
Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. (15388433)
2004
31
Low-activity haplotype of the microsomal epoxide hydrolase gene is protective against placental abruption. (15582499)
2004
32
Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases. (12764376)
2003
33
A controlled longitudinal study of the social functioning of children with juvenile rheumatoid arthritis. (12490627)
2003
34
Value of the preoperative carcinoembryonic antigen as an independent prognostic factor in cancer of the colon and rectum]. (12378215)
2002
35
Unmasking the progesterone receptor in the preoptic area and hypothalamus of the ewe: no colocalization with gonadotropin-releasing neurons. (11159827)
2001
36
Re-evaluation of the thyroxine binding to human plasma lipoproteins using three techniques. (11407661)
2001
37
Klippel-Feil syndrome, thenar hypoplasia, carpal anomalies and situs inversus viscerum. (11045589)
2000
38
Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. (9607416)
1998
39
Differentiation between proteolytic activation and autocatalytic conversion of human prothrombin. Activation of recombinant human prothrombin and recombinant D419N-prothrombin by snake venoms from Echis carinatus and Oxyuranus scutellatus. (8931132)
1996
40
Lipid modifications of trimeric G proteins. (7822269)
1995
41
Brachial plexus neuropathy after radiotherapy for breast cancer. (8520378)
1995
42
Middle and proximal sections of the human internal mammary artery are not "passive conduits". (7934111)
1994
43
Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. (8018669)
1994
44
Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. (8383683)
1993
45
Rosenthal fibers producing a granular cell appearance in a glioblastoma. (8396834)
1993
46
A vase-like shape characterizes the epidermal-mononuclear cell collections seen in spongiotic dermatitis. (2267999)
1990
47
Diphacinone toxicity, von Willebrand's Disease, and Ehrlichia canis in a dog. (3258688)
1988
48
Accommodative esotropia. (13362815)
1956
49
Balanitis xerotica obliterans; a report of two cases. (18118775)
1949
50

Variations for Asperger Syndrome

About this section

Expression for genes affiliated with Asperger Syndrome

About this section
Search GEO for disease gene expression data for Asperger Syndrome.

Pathways for genes affiliated with Asperger Syndrome

About this section

GO Terms for genes affiliated with Asperger Syndrome

About this section

Cellular components related to Asperger Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1synapseGO:00452029.6GABRB3, NLGN3, NLGN4X
2dendriteGO:00304258.7NLGN3, NLGN4X, SGCE, WFS1

Biological processes related to Asperger Syndrome according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1postsynaptic membrane assemblyGO:009710410.3NLGN3, NLGN4X
2presynaptic membrane assemblyGO:009710510.3NLGN3, NLGN4X
3positive regulation of excitatory postsynaptic potentialGO:200046310.3NLGN3, SHANK3
4neuron cell-cell adhesionGO:000715810.3NLGN3, NLGN4X
5vocalization behaviorGO:007162510.3NLGN3, SHANK3
6sperm ejaculationGO:004271310.0OXTR, SLC6A4
7positive regulation of synapse assemblyGO:005196510.0NLGN3, OXTR
8adult behaviorGO:00305349.9NLGN3, NLGN4X, SHANK3
9learningGO:00076129.9NLGN3, SHANK3
10memoryGO:00076139.8SHANK3, SLC6A4
11sensory perception of soundGO:00076059.6GABRB3, WFS1
12positive regulation of synaptic transmission, glutamatergicGO:00519689.6NLGN3, OXTR, SHANK3
13social behaviorGO:00351769.5NLGN3, OXTR

Molecular functions related to Asperger Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neurexin family protein bindingGO:004204310.0NLGN3, NLGN4X

Sources for Asperger Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet